How Does Obesity Cause Large Bowel (Colon and Rectum) Cancer?

Many studies have demonstrated for some time that there is a biological relationship between obesity and large bowel (colorectal) cancer. A study whose results were recently announced showed that a drug approved by the FDA for irritable bowel syndrome could prevent colorectal cancer development. The findings were published in the journal Cancer Research.
Obese people have been shown to have a 50% higher risk of developing colorectal cancer than lean people. In mouse studies at Thomas Jefferson University in Philadelphia investigating the relationship between obesity and colorectal cancer, obesity associated with excessive fat, carbohydrate consumption, or both was found to be related to loss of the hormone guanylin and its activity. Guanylin is a protein hormone produced in the secretory surface cells of the intestine called goblet cells.
The surface of the intestines is highly active and constantly renews itself. A receptor, guanylyl cyclase C (GUCY2C), contributes to this regeneration. Guanylin is the hormone that stimulates this receptor.
The findings showed that a high-calorie diet switches off guanylin expression in the intestine, leading to inactivation of the tumor suppression pathway.
Low Guanylin Expression Sets the Stage for Tumors
One characteristic of colorectal cancer is inactivation of the guanylin gene. This occurs in both humans and animals. Guanylin gene expression is 80% lower in obese people than in lean people.
The guanylin hormone receptor has been found to function as a tumor-suppressing growth control. Without this hormone, the receptor remains silent from the early stages of cancer. This causes the epithelium to lose its function and creates conditions for cancer development.
To verify their findings, the researchers created mice with transgenes that prevented the guanylin gene from being switched off. In this way, cancer development was prevented by switching on the tumor suppressor even when the mice consumed excessive calories.
The research showed that the hormone and its receptor were more silent in obese mice than in lean mice. This study suggested that colorectal cancer could be prevented by giving obese people hormone replacement treatment, just as diabetes is treated with insulin.
The researchers conducting the study believe they have finally found a major clue to the origin of colorectal cancer in obese people, and perhaps in other people as well. They also believe that colorectal cancer develops through this silent mechanism and that this development occurs more often in obese people.
Linaclotide Could Replace the Missing Hormone
Additional findings showed that a drug structurally related to the missing hormone, linaclotide (Linzess) could be used to prevent colorectal cancer in obese people.
Linaclotide was approved by the United States Food and Drug Administration (FDA) in 2012 to treat the constipation form of irritable bowel syndrome and chronic constipation of unknown cause, known as chronic idiopathic constipation.
The researchers also showed that calorie restriction reversed excessive calorie consumption and restored guanylin expression even in obese mice, and recommended lifestyle changes.
Further research is needed to identify this molecular mechanism that stops hormone production. Meanwhile, studies on the dose and adverse effects of linaclotide are continuing.
Sources
Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin–GUCY2C Paracrine Signaling Axis.
Cancer Res. 2016 Jan 15;76(2):339-46. doi: 10.1158/0008-5472.CAN-15-1467-T.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.